Dedalus closes acquisition of DXC Technology’s healthcare software business

The company specializing in digital health and diagnostics has announced the successful closing of the acquisition of DXC Technology’s global healthcare information technology (ICT) business. Dedalus thus strengthens its position as a specialist healthcare ICT company with one of the largest digital health research and development teams in Europe. The amount of the transaction has not been disclosed, although at the time of the deal’s inception it was estimated at $551 million (€459 million.) The company has a portfolio of digital health solutions in the areas of clinical and hospital, primary and social care, connected health and care coordination, diagnostics, and life sciences, among others.

The acquisition enables Dedalus to accelerate the digital transformation of the healthcare ecosystem with expanded research and development (R&D) capabilities. Dedalus currently has a turnover of more than $845 million (€700 million), works with more than 6,100 hospitals and 5,300 laboratories worldwide. The company has more than 5,500 professionals and a digital health R&D team of more than 2,000 people, 35% of its workforce.

If you want to find more details about Dedalus and to read the latest finance news in the world, download for free the Born2Invest mobile app.

Dedalus will grow this year in Spain in both business and R&D

With this acquisition, the company aims to expand its business in the main European markets, expand into new markets around the world and establish a highly qualified management team, led by Dedalus CEO Andrea Fiumicelli and company president Giorgio Moretti. In Spain, Dedalus has more than thirty years of experience in the design, development, and implementation of information technology solutions and services for healthcare. In addition, the company has one of Dedalus’ global R&D hubs in the country, with five centers of excellence for the design and development of digital health solutions that are marketed and implemented worldwide.

“Dedalus will grow this year in Spain, both in business and R&D,” said Dedalus Iberia CEO Marisa Felipe. She explained that business growth will be based on transformation and improvement projects in systems already deployed and on the deployment of new systems focused on clinical data management. The company is looking for more than thirty positions in Spain in the areas of engineering and delivery.

For his part, Moretti said that “this year we will launch a new digital health platform and our solutions that will drive and support the creation of new and innovative digital health models.”

__

(Featured image by kkolosov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.